| |
| Overview |
| ················································ |
| Team |
| ················································ |
| SAB |
| ················································ |
| Board |
| ················································ |
| Investors |
| ················································ |
| Events&News |
| ················································ |
|
Crystax Pharmaceuticals and Uriach sign a contract for new anti-inflammatory drug development
17 December, 2004
Biotech company Crystax Pharmaceuticals and Uriach Laboratories have come to an agreement for the development of new anti-inflammatory drugs. The research contract between the companies, with headquarters in the Barcelona Science Park, establishes the structure determination of a target protein by X-ray crystallography and the later molecular screening for hit-to-lead candidates.
Crystax is a pioneering firm in the Spanish biotech market focused in structure determination technology. Uriach is a pharma company established in 1838 with a wide presence in Spain.
|
|
